Betta Pharmaceuticals announced that the marketing license application for ensartinib hydrochloride capsules declared by the company's holding subsidiary Xdiscovery received positive opinions from the European Medicines Agency's Human Medicines Committee, and the CHMP recommended approval of the drug for the treatment of adult patients with advanced anaplastic lymphoma kinase positive advanced non-small cell lung cancer. The European Commission will make a final decision based on CHMP's positive opinion. There is still uncertainty about whether the listing license application will be approved, and it is expected that it will not have a significant impact on the company's business performance in the short term.

Betta Pharmaceuticals announced that the marketing license application for ensartinib hydrochloride capsules declared by the company's holding subsidiary Xdiscovery received positive opinions from the European Medicines Agency's Human Medicines Committee, and the CHMP recommended approval of the drug for the treatment of adult patients with advanced anaplastic lymphoma kinase positive advanced non-small cell lung cancer. The European Commission will make a final decision based on CHMP's positive opinion. There is still uncertainty about whether the listing license application will be approved, and it is expected that it will not have a significant impact on the company's business performance in the short term.